Skip to main content
JHS Svendgaard Laboratories Ltd. logo

JHS Svendgaard Laboratories Ltd. — Investor Relations & Filings

Ticker · JHS ISIN · INE544H01014 LEI · 335800NYNAOOMRTTWW75 BSE.NS Manufacturing
Open in API
Filings indexed 678 across all filing types
Latest filing 2025-02-11 Regulatory Filings
Country IN India
Listing BSE.NS JHS

About JHS Svendgaard Laboratories Ltd.

https://www.svendgaard.com/

JHS Svendgaard Laboratories Ltd. is a specialized manufacturer of oral care products, operating primarily through contract manufacturing and private labeling arrangements. The company provides end-to-end solutions for oral hygiene, including the production of toothbrushes, toothpastes, mouthwashes, and specialized dental care items. It maintains large-scale manufacturing facilities equipped to handle high-volume production for global and domestic FMCG brands. In addition to its business-to-business operations, the company manages its own consumer brand, Aquawhite, which focuses on innovative oral care solutions for various age groups, including a significant range of licensed character-based products for children. The organization emphasizes quality control and technical expertise in oral health product development, catering to diverse market segments through a robust supply chain and distribution network.

Recent filings

Filing Released Lang Actions
Financial Result Updates
Regulatory Filings
2025-02-11 English
Outcome of Board Meeting
Regulatory Filings
2025-02-11 English
Statement of deviation(s) or variation(s) under Reg. 32
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges regarding the statement of deviation or variation in utilization of funds raised under SEBI regulations for the quarter ended December 31, 2024. It includes details about the preferential issue, amount raised, and confirms no deviation in the use of funds. The document is a regulatory compliance filing related to fund utilization reporting, not a full financial report or earnings release. It is a specific regulatory announcement under SEBI Listing Obligations and Disclosure Requirements, 2015, Regulation 32. The document length is 4163 characters, which is relatively short and focused on a specific regulatory disclosure rather than a comprehensive report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document rather than a full financial report or capital update.
2025-02-11 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-02-06 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal notice addressed to stock exchanges regarding an upcoming Board of Directors meeting scheduled for February 11, 2025. The purpose of the meeting is to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2024. The document references regulatory compliance under SEBI LODR Regulations and insider trading regulations. It does not contain the financial results themselves but rather informs about the meeting where these results will be approved and subsequently announced. The document length is short (1825 characters) and serves as an announcement or intimation rather than the actual financial report. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement and compliance notice rather than an Interim Report (IR) or Earnings Release (ER).
2025-02-06 English
Copy of Newspaper Publication
Regulatory Filings
2025-01-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.